Matthew P. Coghlan

4.1k citations

33 papers · 2.7k indexed · 3 hit papers · h-index 20

Molecular Biology top 5%
Endocrinology, Diabetes and Metabolism top 1%
Surgery top 5%
Physiology top 5%
Pharmacology top 5%

Co-authors: Kyle W. Sloop Ricardo J. Samms Brendan Leighton Neil Pearce Julie C. Holder Stacey L. Corcoran John Yates Gregory Murphy
Topics: Diabetes Treatment and Management (14 papers)Pancreatic function and diabetes (13 papers)Metabolism, Diabetes, and Cancer (12 papers)
Cited by: Endocrinology, Diabetes and Metabolism Molecular Biology Pharmacology
Journals: Proceedings of the National Academy of Sciences Journal of Biological Chemistry Nature Medicine
Partner nations: United Kingdom United States Denmark

In The Last Decade

Matthew P. Coghlan

30 papers receiving 2.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription

2000 771 citations Matthew P. Coghlan, Ainsley A. Culbert et al. Chemistry & Biology profile →
Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist

2020 314 citations Francis S. Willard, Jonathan D. Douros et al. JCI Insight profile →
How May GIP Enhance the Therapeutic Efficacy of GLP-1?

2020 276 citations Ricardo J. Samms, Matthew P. Coghlan et al. Trends in Endocrinology and Metabolism profile →

Peers

Countries citing papers authored by Matthew P. Coghlan

Since Specialization

Citations

This map shows the geographic impact of Matthew P. Coghlan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew P. Coghlan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew P. Coghlan more than expected).

Fields of papers citing papers by Matthew P. Coghlan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthew P. Coghlan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew P. Coghlan. The network helps show where Matthew P. Coghlan may publish in the future.

Co-authorship network of co-authors of Matthew P. Coghlan

This figure shows the co-authorship network connecting the top 25 collaborators of Matthew P. Coghlan. A scholar is included among the top collaborators of Matthew P. Coghlan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matthew P. Coghlan. Matthew P. Coghlan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	GLP ‐ 1R biased cAMP agonism maintains glycemic control with reduced malaise and emesis in preclinical mammalian models 2026 ·Diabetes Obesity and Metabolism ·(unknown),(unknown),Alex D. White,(unknown),(unknown),(unknown),(unknown),Amy Xiao,(unknown),(unknown),(unknown),Matthew P. Coghlan,Erik T. Bodor,(unknown),(unknown),(unknown),(unknown),(unknown),(unknown)	0
2	Tirzepatide leads to weight reduction in people with obesity due to MC4R deficiency 2025 ·Nature Medicine ·Pallav Bhatnagar,Nadia N. Ahmad,(unknown),Matthew P. Coghlan,Lee M. Kaplan,I. Sadaf Farooqi	1
3	PULMONARY BLASTOMYCOSIS PRESENTING AS ACUTE RESPIRATORY DISTRESS SYNDROME 2024 ·CHEST Journal ·(unknown),Matthew P. Coghlan	0
4	FATAL CASE OF SEVERE ACUTE NECROTIZING PANCREATITIS IN THE SETTING OF RECENT GLP-1 RECEPTOR AGONIST INITIATION 2024 ·CHEST Journal ·J. Stuart,(unknown),Matthew P. Coghlan,(unknown),W. Graham Carlos	0
5	Genetically Predicted Glucose-Dependent Insulinotropic Polypeptide (GIP) Levels and Cardiovascular Disease Risk Are Driven by Distinct Causal Variants in the GIPR Region 2021 ·Diabetes ·Nicholas Bowker,(unknown),Stephen Burgess,Christopher N. Foley,Victoria P.W. Auyeung,A. Mesut Erzurumluoglu,Isobel D. Stewart,Eleanor Wheeler,Maik Pietzner,Fiona M. Gribble,Frank Reimann,Pallav Bhatnagar,Matthew P. Coghlan,Nicholas J. Wareham,Claudia Langenberg	16
6	Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonistbreakdown → 2020 ·JCI Insight ·Francis S. Willard,Jonathan D. Douros,M Gabe,Aaron D. Showalter,David B. Wainscott,Todd M. Suter,Megan E. Capozzi,Wijnand J. C. van der Velden,Cynthia Stutsman,Guemalli R. Cardona,Shweta Urva,Paul J. Emmerson,Jens J. Holst,David A. D’Alessio,Matthew P. Coghlan,Mette M. Rosenkilde,Jonathan E. Campbell,Kyle W. Sloop	314
7	How May GIP Enhance the Therapeutic Efficacy of GLP-1?breakdown → 2020 ·Trends in Endocrinology and Metabolism ·Ricardo J. Samms,Matthew P. Coghlan,Kyle W. Sloop	276
8	Inhalational Anesthetics Induce Neuronal Protein Aggregation and Affect ER Trafficking 2018 ·Scientific Reports ·Matthew P. Coghlan,(unknown),(unknown),(unknown),(unknown),Saumel Ahmadi,(unknown),Mark W. Crawford,Jason T. Maynes	14
9	A GLP-1:CCK fusion peptide harnesses the synergistic effects on metabolism of CCK-1 and GLP-1 receptor agonism in mice 2018 ·Appetite ·David C. Hornigold,(unknown),Victor Howard,Sarah Will,Stephanie Oldham,Matthew P. Coghlan,Clémence Blouet,James L. Trevaskis	31
10	Development and characterisation of a novel glucagon like peptide-1 receptor antibody 2017 ·Diabetologia ·Emma K. Biggs,Lihuan Liang,Jacqueline Naylor,Shimona Madalli,(unknown),Matthew P. Coghlan,David Baker,David C. Hornigold,Peter Ravn,Frank Reimann,Fiona M. Gribble	25
11	Gut check on diabesity: leveraging gut mechanisms for the treatment of type 2 diabetes and obesity 2017 ·Current Opinion in Pharmacology ·Sarah Will,David C. Hornigold,David Baker,Matthew P. Coghlan,(unknown),James L. Trevaskis,Jacqueline Naylor	11
12	Chronic glucokinase activation reduces glycaemia and improves glucose tolerance in high-fat diet fed mice 2011 ·European Journal of Pharmacology ·Maria Sörhede Winzell,Matthew P. Coghlan,Brendan Leighton,Georgia Frangioudakis,David M. Smith,Leonard H Storlien,Bo Åhrén	27
13	Glucokinase activators in diabetes management 2008 ·Expert Opinion on Investigational Drugs ·Matthew P. Coghlan,Brendan Leighton	93
14	Predictive blood glucose lowering efficacy by Glucokinase activators in high fat fed female Zucker rats 2006 ·British Journal of Pharmacology ·(unknown),(unknown),(unknown),Darren McKerrecher,Craig Johnstone,Kurt G. Pike,Petter Holme,(unknown),Débora Gil,Matthew P. Coghlan,Brendan Leighton	67
15	Development of glucose intolerance in male transgenic mice overexpressing human glycogen synthase kinase-3β on a muscle-specific promoter 2004 ·Metabolism ·Neil Pearce,Jonathan R.S. Arch,John C. Clapham,Matthew P. Coghlan,Stacey L. Corcoran,Carolyn A. Lister,Andrea Llano,Gary B.T. Moore,Gregory Murphy,Stephen A. Smith,(unknown),John Yates,Alastair Morrison,Alexander James Harper,(unknown),Alejandro Abuin,Edward T. Wargent,Julie C. Holder	90
16	Use of lithium and SB‐415286 to explore the role of glycogen synthase kinase‐3 in the regulation of glucose transport and glycogen synthase 2003 ·European Journal of Biochemistry ·Katrina MacAulay,Éric Hajduch,(unknown),Matthew P. Coghlan,Stephen A. Smith,Harinder S. Hundal	55
17	Inactivation of phosphorylase is a major component of the mechanism by which insulin stimulates hepatic glycogen synthesis 2003 ·European Journal of Biochemistry ·Susan Aiston,Matthew P. Coghlan,Loranne Agius	48
18	Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcriptionbreakdown → 2000 ·Chemistry & Biology ·Matthew P. Coghlan,Ainsley A. Culbert,Darren A.E. Cross,Stacey L. Corcoran,John Yates,Neil Pearce,Oliver Rausch,Gregory Murphy,Paul S. Carter,(unknown),David Mills,Murray J. B. Brown,David Haigh,Robert W. Ward,David G. Smith,Kenneth Murray,Alastair D. Reith,Julie C. Holder	771
19	c-Jun Is a JNK-independent Coactivator of the PU.1 Transcription Factor 1999 ·Journal of Biological Chemistry ·Gerhard Behre,Alan J. Whitmarsh,Matthew P. Coghlan,Trang Hoang,Christopher L. Carpenter,Dong‐Er Zhang,Roger J. Davis,Daniel G. Tenen	151
20	Characterization of pICln phosphorylation state and a pICln-associated protein kinase 1998 ·Biochimica et Biophysica Acta (BBA) - General Subjects ·Roberto Sánchez‐Olea,Francesco Emma,Matthew P. Coghlan,Kevin Strange	18

About Matthew P. Coghlan

Matthew P. Coghlan is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Surgery, having authored 33 papers that have together received 2.7k indexed citations. Recurring topics across this work include Diabetes Treatment and Management (14 papers), Pancreatic function and diabetes (13 papers) and Metabolism, Diabetes, and Cancer (12 papers). The work is most often cited by research in Endocrinology, Diabetes and Metabolism (905 citations), Molecular Biology (1.7k citations) and Pharmacology (325 citations). Matthew P. Coghlan has collaborated with scholars based in United Kingdom, United States and Denmark. Frequent co-authors include Kyle W. Sloop, Ricardo J. Samms, Brendan Leighton, Neil Pearce, Julie C. Holder, Stacey L. Corcoran, John Yates, Gregory Murphy, Calum Sutherland and Pamela A. Lochhead. Their work appears in journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Nature Medicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact